Onconetix Presents Innovative Data at EAU Congress
Onconetix, Inc. (Nasdaq: ONCO), a leader in cancer diagnostics, is making waves in the medical community with its innovative prostate cancer test, Proclarix. The company has recently announced that a significant abstract concerning Proclarix has been accepted for presentation at the prestigious European Association of Urology (EAU) Congress. This event is set to take place over four days and represents an opportunity for Onconetix to share important clinical findings with international experts.
Focusing on Early Detection
Proclarix, a biomarker-based blood test, is designed to help in the early detection of prostate cancer. The upcoming presentation titled “Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort” will delve into performance results derived from a robust study featuring over 800 patients. These patients were meticulously recruited from Lillebaelt Hospital, part of the University Hospital of Southern Denmark.
Key Highlights from the Presentation
The presentation promises to shed light on how Proclarix has already shown the ability to reduce unnecessary biopsy procedures by identifying patients who are less likely to have clinically significant cancer. Ralph Schiess, PhD, the CEO of Proteomedix, a subsidiary of Onconetix, stated that this test significantly enhances patient care by minimizing risks associated with prostate biopsies compared to traditional methods.
Details of the EAU Presentation
Audience members at the EAU Congress can look forward to detailed information during the session scheduled for March 23. Chief among the topics will be the validation of Proclarix's capabilities in the context of diagnosing prostate cancer, vital as increasing numbers of men face prostate health challenges.
Understanding Proclarix's Impact
Proclarix is CE-certified and adheres to the In Vitro Diagnostic Regulation (IVDR). It is indicated for diagnosis in cases where patients exhibit normal digital rectal exams (DRE) alongside enlarged prostate volumes and elevated PSA levels ranging between 2-10 ng/ml. The risk assessment conducted through Proclarix is derived from in-vitro assays that measure biomarkers in blood serum. Thus, its risk score has been validated across multiple clinical studies as a reliable predictor of significant prostate cancer presence.
About Onconetix and Its Commitment
As a commercial-stage biotechnology company, Onconetix is dedicated to pioneering solutions in men’s health and oncology. The recent acquisition of Proteomedix has strengthened its portfolio, enabling the company to not only promote Proclarix in the EU but also prepare for its anticipated entry into the U.S. market as a lab-developed test (LDT) through a collaboration with Labcorp. Beyond Proclarix, Onconetix's offerings include ENTADFI, an FDA-approved medication combining finasteride and tadalafil for treating benign prostatic hyperplasia (BPH).
Contacting Onconetix
The commitment of Onconetix to advancing diagnostic solutions is reinforced by its strong investor and media relations. For inquiries or further information regarding their products and initiatives, stakeholders can reach out through the dedicated contacts provided.
Frequently Asked Questions
What is Proclarix?
Proclarix is a biomarker-based blood test developed for the diagnosis of prostate cancer in patients showing specific medical indicators.
What are the key benefits of Proclarix?
Proclarix helps identify patients who are unlikely to have clinically significant prostate cancer, potentially reducing unnecessary biopsies.
How has Proclarix been validated?
Proclarix has been validated in several clinical studies that demonstrate its reliability in detecting clinically significant prostate cancer.
Where was the Proclarix study conducted?
The study involved over 800 patients recruited from Lillebaelt Hospital, a significant center for oncology research in Denmark.
How can I contact Onconetix for more information?
Investors and interested parties can reach Onconetix through their investor relations email or the contact information available on their official website.
